New drug combo before transplant shows promise for blood cancer patients
NCT ID NCT02250937
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 27 times
Summary
This study tests a new combination of chemotherapy drugs (venetoclax, busulfan, cladribine, and fludarabine) given before a donor stem cell transplant in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to kill cancer cells and make room for healthy donor stem cells to grow. The trial includes 116 adults aged 18-70 with a matched donor, and it measures how long patients stay cancer-free and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.